Alterity Therapeutics Issues 18M Options, Signaling Near 100% Potential Dilution
Summary
Alterity Therapeutics has issued 18 million unlisted options under an employee incentive scheme, which, if exercised, could nearly double the company's US-equivalent shares outstanding, leading to substantial dilution for existing shareholders.
Key Events
-
Issuance of Unlisted Options
Alterity Therapeutics issued 18,000,000 unlisted options on January 15, 2026.
-
Employee Incentive Scheme
The options were granted under an employee incentive scheme, not directly to key management personnel.
-
Significant Potential Dilution
If exercised, these options represent a potential increase of nearly 100% in the company's US-equivalent shares outstanding, based on the current market capitalization and stock price.
-
Deeply In-The-Money Options
The options have an exercise price of AUD 0.008 and expire in 2031, making them deeply in-the-money compared to the current US stock price of $3.40.
Analysis
Alterity Therapeutics has issued a substantial number of unlisted options under an employee incentive scheme. While not directly granted to key management personnel, the 18 million options represent a potential increase of nearly 100% in the company's US-equivalent shares outstanding, based on the current market capitalization and stock price. This level of potential dilution is highly significant and could materially impact the value of existing shares. The options' deeply in-the-money exercise price of AUD 0.008, compared to the current US stock price of $3.4, makes their eventual exercise highly probable, posing a considerable overhang on the stock.
At the time of this filing, ATHE was trading at $3.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $61.8M. The 52-week trading range was $2.52 to $7.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.